Table of Content



Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.12 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Industry Outlook
3.1 Market Variable Analysis
3.2 Driver Impact Analysis
3.2.1 Presence of Strong Product Pipeline
3.2.2 Growing Geriatric Population Base
3.2.3 Increasing Incidence and Prevalence of Cancer
3.3 Market Restraint Analysis
3.3.1 High Manufacturing Cost of Antibody-Drug Conjugates and Challenges in Downstream Processing Of ADCs
3.3.2 Stringent Reimbursement Policies for ADCs
3.4 Penetration and Growth Prospect Mapping
3.5 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.6 Porter’s Five Forces Analysis
Chapter 4 Application Business Analysis
4.1 Antibody-Drug Conjugates Market: Application Movement Analysis
4.2 Blood Cancer
4.2.1 Blood Cancer Market Estimates And Forecast, 2017 - 2028
4.2.2 Leukemia
4.2.2.1 Leukemia Market Estimates And Forecast, 2017 - 2028
4.2.3 Multiple Myeloma
4.2.3.1 Multiple Myeloma Market Estimates And Forecast, 2017 - 2028
4.2.4 Lymphoma
4.2.4.1 Lymphoma Market Estimates And Forecast, 2017 - 2028
4.3 Breast Cancer
4.3.1 Breast Cancer Market Estimates And Forecast, 2017 - 2028
4.4 Urothelial Cancer & Bladder Cancer
4.4.1 Urothelial Cancer & Bladder Cancer Market Estimates And Forecast, 2017 - 2028
4.5 Others
4.5.1 Others Market Estimates And Forecast, 2017 - 2028
Chapter 5 Technology Business Analysis
5.1 Antibody-Drug Conjugates Market: Technology Movement Analysis
5.2 Cleavable Linker
5.2.1 Cleavable Linker Market Estimates And Forecast, 2017 - 2028
5.3 Non-cleavable Linker
5.3.1 Non-Cleavable Linker Market Estimates And Forecast, 2017 - 2028
5.4 Linkerless
5.4.1 Linkerless Market Estimates And Forecast, 2017 - 2028
Chapter 6 Regional Business Analysis
6.1 Antibody-Drug Conjugates Market: Regional Movement Analysis
6.2 North America
6.2.1 North America Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.2.2 The U.S.
6.2.2.1 The U.S. market estimates and forecast, 2017 - 2028 (USD Million)
6.2.3 Canada
6.2.3.1 Canada market estimates and forecast, 2017 - 2028 (USD Million)
6.3 Europe
6.3.1 Europe Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.3.2 The U.K.
6.3.2.1 The U.K. market estimates and forecast, 2017 - 2028 (USD Million)
6.3.3 Germany
6.3.3.1 Germany market estimates and forecast, 2017 - 2028 (USD Million)
6.3.4 Italy
6.3.4.1 Italy market estimates and forecast, 2017 - 2028 (USD Million)
6.3.5 Spain
6.3.5.1 Spain market estimates and forecast, 2017 - 2028 (USD Million)
6.3.6 France
6.3.6.1 France market estimates and forecast, 2017 - 2028 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.4.2 Japan
6.4.2.1 Japan Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.4.3 China
6.4.3.1 China Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.4.4 India
6.4.4.1 India Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.4.5 Australia
6.4.5.1 Australia Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.4.6 South Korea
6.4.6.1 South Korea Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.5 Latin America
6.5.1 Latin America Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.5.3 Mexico
6.5.3.1 Mexico Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.5.4 Argentina
6.5.4.1 Argentina Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.6 Middle East & Africa
6.6.1 Middle-East And Africa Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.6.3 Saudi Arabia
6.6.3.1 Saudi Arabia Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.6.4 UAE
6.6.4.1 UAE Market Estimates And Forecast, 2017 - 2028 (USD Million)
Chapter 7 Competitive Landscape
7.1 Major deals & strategic alliances analysis
7.1.1 New product launch
7.1.2 Mergers and acquisitions
7.1.3 Expansion
7.1.4 Partnerships
7.2 Vendor Landscape
7.2.1 List Of Key Distributors And Channel Partners
7.2.2 Key Company Market Share Analysis, 2020
7.3 Public Companies
7.3.1 Company Market Position Analysis
7.3.2 Competitive Dashboard Analysis
7.4 Private Companies
7.4.1 List Of Key Emerging Companies/Technology Disruptors/ Innovators
Chapter 8 Company Profiles
8.1 Takeda Pharmaceutical Company Limited
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 Product Benchmarking
8.1.4 Strategic Initiatives
8.2 F. Hoffmann-La Roche Ltd.
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Product Benchmarking
8.2.4 Strategic Initiatives
8.3 Pfizer, Inc.
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 Product Benchmarking
8.3.4 Strategic Initiatives
8.4 Astrazeneca
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Product Benchmarking
8.4.4 Strategic Initiatives
8.5 Gilead Sciences, Inc.
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Product Benchmarking
8.5.4 Strategic Initiatives
8.6 Astellas Pharma
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 Product Benchmarking
8.6.4 Strategic Initiatives
8.7 Seagen, Inc.
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Product Benchmarking
8.7.4 Strategic Initiatives
8.8 Daiichi Sankyo Company, Limited
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Product Benchmarking
8.8.4 Strategic Initiatives
8.9 GlaxoSmithKline Plc
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Product Benchmarking
8.9.4 Strategic Initiatives
8.10 ADC Therapeutics
8.10.1 Company Overview
8.10.2 Financial Performance
8.10.3 Product Benchmarking
8.10.4 Strategic Initiatives



List of Figures

List of Figures

Fig. 1 Antibody-drug conjugates market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Antibody-drug conjugates market snapshot
Fig. 10 Antibody-drug conjugates market driver impact
Fig. 11 Global population by age group, 2016, 2020, & 2027
Fig. 12 Global cancer cases projection,2020-2030 (Number of newly registered cases)
Fig. 13 Antibody-drug conjugates market restraint impact
Fig. 14 Penetration and growth prospect mapping
Fig. 15 SWOT analysis, by factor (political & legal economic and technological)
Fig. 16 Porter’s five forces analysis
Fig. 17 Antibody-drug conjugates market: Application outlook and key takeaways
Fig. 18 Antibody-drug conjugates market: Application movement analysis
Fig. 19 Blood cancer market estimates and forecasts, 2017 - 2028
Fig. 20 Leukemia market estimates and forecasts, 2017 - 2028
Fig. 21 Multiple Myeloma market estimates and forecasts, 2017 - 2028
Fig. 22 Lymphoma market estimates and forecasts, 2017 - 2028
Fig. 23 Breast cancer market estimates and forecasts, 2017 - 2028
Fig. 24 Urothelial cancer market estimates and forecasts, 2017 - 2028
Fig. 25 Others market estimates and forecasts, 2017 - 2028
Fig. 26 Antibody-drug conjugates market: Technology outlook and key takeaways
Fig. 27 Antibody-drug conjugates market: Technology movement analysis
Fig. 28 Cleavable linker market estimates and forecasts, 2017 - 2028
Fig. 29 Non-cleavable linker market estimates and forecasts, 2017 - 2028
Fig. 30 Linkerless market estimates and forecasts, 2017 - 2028
Fig. 31 Antibody-drug conjugates market: Regional outlook and key takeaways
Fig. 32 Antibody-drug conjugates market: Regional movement analysis
Fig. 33 North America
Fig. 34 North America market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 35 The U.S.
Fig. 36 The U.S. market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 37 Canada
Fig. 38 Canada market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 39 Europe
Fig. 40 Europe market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 41 The U.K.
Fig. 42 The U.K. market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 43 Germany
Fig. 44 Germany market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 45 Italy
Fig. 46 Italy market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 47 Spain
Fig. 48 Spain market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 49 France
Fig. 50 France market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 51 Asia Pacific
Fig. 52 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 53 Japan
Fig. 54 Japan market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 55 China
Fig. 56 China market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 57 India
Fig. 58 India market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 59 Australia
Fig. 60 Australia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 61 South Korea
Fig. 62 South Korea market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 63 Latin America
Fig. 64 Latin America market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 65 Brazil
Fig. 66 Brazil market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 67 Mexico
Fig. 68 Mexico market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 69 Argentina
Fig. 70 Argentina market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 71 Middle East & Africa
Fig. 72 Middle East and Africa market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 73 South Africa
Fig. 74 South Africa market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 75 Saudi Arabia
Fig. 76 Saudi Arabia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 77 UAE
Fig. 78 UAE market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 79 Company market share analysis
Fig. 80 Company market position analysis (Revenue US$ mn)
Fig. 81 Company market position analysis (Profit Margin)
Fig. 82 Competitive dashboard analysis
Fig. 83 Regional Network Map

List of Tables

List of Tables

TABLE 1 List of secondary sources
TABLE 2 List of Abbreviations
TABLE 3 North America antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 4 North America antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 5 The U.S. antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 6 The U.S. antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 7 Canada antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 8 Canada antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 9 Europe antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 10 Europe antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 11 The U.K. antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 12 The U.K. antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 13 Germany antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 14 Germany antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 15 France antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 16 France antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 17 Italy antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 18 Italy antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 19 Spain antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 20 Spain antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 21 Asia Pacific antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 22 Asia Pacific antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 23 Japan antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 24 Japan antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 25 China antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 26 China antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 27 India antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 28 India antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 29 Australia antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 30 Australia antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 31 South Korea antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 32 South Korea antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 33 Latin America antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 34 Latin America antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 35 Brazil antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 36 Brazil antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 37 Mexico antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 38 Mexico antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 39 Argentina antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 40 Argentina antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 41 MEA antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 42 MEA antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 43 South Africa antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 44 South Africa antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 45 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 46 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 47 UAE antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 48 UAE antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 49 List of key distributors
TABLE 50 List of key emerging companies/technology disruptors/innovators